Dornier MedTech Launches UroX, a new community to boost innovation in the field of urology

Return to all news

Singapore, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Dornier MedTech (Dornier), the pioneer of non-invasive Extracorporeal Shockwave Lithotripsy (ESWL) technology and global leader in stone management, today announced that it is launching UroX, a community that connects professionals from various disciplines to cultivate innovation and solve the most pressing challenges in urology.

Over 900 million people suffer from urological disorders globally, and urological patients face some of the greatest pains and deadly conditions. Innovative treatment options require collaboration between multiple parties, including clinicians, corporations, academics, researchers, government and private funding organizations, engineers, and entrepreneurs. Taking the lead to drive innovative urological treatment, Dornier launched UroX to connect talents, technologies, and funding to solve critical problems facing urology today. Two new initiatives will be rolled out for the UroX community: The UroXChallenge and UroXChange.

UroX Challenge
The UroXChallenge is Asia’s largest medtech call for innovations in urology, where up to SGD$500k of funding will be offered to innovative proposals with the potential to make a breakthrough in urological patient care and treatment. Areas of interest include kidney stones, urological cancers, urinary incontinence, medical devices, digital solutions and precision medicine. Throughout the challenge, technical, clinical as well as commercial mentorship will be provided to the participants, to help them bring their innovations closer to market.

The UroXChallenge is organized in collaboration with A*ccelerate, the commercialization arm of the Agency for Science, Technology and Research (A*STAR), National Health Innovation Centre Singapore (NHIC), a provider of translational funding and strategic guidance to publicly-funded clinical research, and Advanced MedTech, a global medical technology leader with a core focus in urology devices and services.

UroXChange
Dornier is also organizing UroXChange, a series of webinars and events that aim to provide the UroX community the knowledge and expertise from renowned opinion leaders in urology space, including academics and clinicians. In the inaugural webinar on 6 August, leading urology clinicians in Singapore will share their experiences and urgent needs for innovation in urology and invite people of distinct expertise and background to take up the challenge to solve unmet needs in the industry.

Yau Chung Wong, Chief Operating Officer at Dornier MedTech said, “UroX community aims to facilitate and accelerate innovations in urology by connecting innovators of various background and the resources they need to succeed. We’re glad to have the support of local incubators and like-minded organizations, and hope to ultimately bring more creative treatment options to benefit patients and physicians.”

To know more about the UroX community and UroXChallenge, please visit https://www.dornier.com/urox/.

Ends

Media Contact:

Emma Thompson / Tianning He / Maryanne Lee
Spurwing Communications
Advanced@spurwingcomms.com
 

About Dornier MedTech
Dornier MedTech is headquartered in Munich, Germany, and is a full subsidiary of Advanced MedTech.

Dornier is a medical device company focused on providing leading technology and improving life by delivering scientifically superior products and solutions to physicians, healthcare providers and research groups involved in urological care.

As pioneers of the lithotripsy and a variety of surgical lasers, Dornier’s 40 years of innovation and service have made it one of the most trusted MedTech companies in the industry.

About Advanced MedTech
Advanced MedTech Holdings is a global medical technology leader with a core focus in urology devices and services. Headquartered in Singapore, with operations in US, Germany, Spain, France, Italy, China, Malaysia and Japan, the Company serves millions of patients and physicians in 100 countries worldwide. Advanced MedTech Holdings makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world. Advanced MedTech Holdings is a wholly-owned subsidiary of Temasek. For more information on Advanced MedTech Holdings, please visit www.advanced-medtech.com.

About A*ccelerate
A*ccelerate is the commercialisation arm of the Agency for Science, Technology and Research (A*STAR) , supporting it in transforming the economy by driving innovation and commercialising its research outcomes.

About the Agency for Science, Technology and Research (A*STAR)

A*STAR is Singapore's lead public sector R&D agency, spearheading economic-oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.

As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability. 

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR’s R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

About National Health Innovation Centre Singapore (NHIC)
The National Health Innovation Centre Singapore provides the publicly-funded clinical research sector of Singapore with translational funding and strategic guidance to accelerate healthcare innovation. Established in 2014, NHIC impacts the clinical landscape by accelerating the development of innovative technologies and services to improve healthcare delivery and patient care. NHIC funding and guidance supports the translation of an innovation by validating, de-risking or developing it towards a market-ready product. By promoting the collaboration of researchers, clinicians and industry, NHIC strives to better position Singapore to tackle healthcare challenges of tomorrow. For more information visit www.nhic.sg


By: GlobenewsWire - 06 Aug 2020
Return to all news

Explore our database of over 50,000 companies